Stockscreener 앱 받기
36.97
1.68%
0.61
시간 외 거래:
36.97
전일 마감가:
$36.36
열려 있는:
$37.04
하루 거래량:
992.46K
Relative Volume:
0.92
시가총액:
$2.20B
수익:
$66.05M
순이익/손실:
$-422.60M
주가수익비율:
-5.0986
EPS:
-7.251
순현금흐름:
$-384.73M
1주 성능:
-7.71%
1개월 성능:
-2.45%
6개월 성능:
+28.95%
1년 성능:
-7.58%
1일 변동 폭
$36.23
$38.74
1주일 범위
$35.09
$39.37
52주 변동 폭
$22.24
$46.00
Agios Pharmaceuticals Inc Stock (AGIO) Company Profile
명칭
Agios Pharmaceuticals Inc
전화
617-649-8600
주소
88 SIDNEY STREET, CAMBRIDGE, MA
Compare AGIO vs VRTX, REGN, ARGX, RVMD, ALNY
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AGIO
Agios Pharmaceuticals Inc
|
36.97 | 2.16B | 66.05M | -422.60M | -384.73M | -7.251 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Agios Pharmaceuticals Inc Stock (AGIO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-20 | 재확인 | H.C. Wainwright | Buy |
| 2025-11-24 | 개시 | Truist | Buy |
| 2025-11-20 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2025-11-19 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-02-24 | 개시 | H.C. Wainwright | Buy |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-09-27 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-02-08 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-02-03 | 개시 | Piper Sandler | Overweight |
| 2022-11-17 | 업그레이드 | Goldman | Sell → Neutral |
| 2022-07-27 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2021-12-03 | 개시 | BofA Securities | Buy |
| 2021-07-30 | 다운그레이드 | Goldman | Neutral → Sell |
| 2021-07-01 | 개시 | Raymond James | Mkt Perform |
| 2021-06-10 | 개시 | H.C. Wainwright | Buy |
| 2021-03-01 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2021-03-01 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2021-02-26 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2020-10-22 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2020-03-04 | 개시 | Barclays | Equal Weight |
| 2019-11-26 | 개시 | Cantor Fitzgerald | Overweight |
| 2019-09-23 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2019-05-23 | 재개 | Goldman | Neutral |
| 2019-02-15 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2018-09-25 | 개시 | Leerink Partners | Mkt Perform |
| 2018-05-23 | 개시 | Citigroup | Buy |
| 2018-04-11 | 재확인 | Credit Suisse | Outperform |
| 2018-02-15 | 재확인 | Needham | Buy |
| 2018-02-15 | 재확인 | SunTrust | Buy |
| 2017-09-15 | 개시 | RBC Capital Mkts | Outperform |
| 2017-08-10 | 재확인 | Needham | Buy |
| 2017-08-08 | 재확인 | SunTrust | Buy |
| 2017-08-02 | 업그레이드 | Leerink Partners | Mkt Perform → Outperform |
| 2017-06-26 | 다운그레이드 | Janney | Buy → Neutral |
| 2017-01-17 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2016-10-24 | 개시 | Needham | Buy |
| 2016-06-13 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2016-05-18 | 재확인 | SunTrust | Buy |
모두보기
Agios Pharmaceuticals Inc 주식(AGIO)의 최신 뉴스
Agios Pharmaceuticals Inc (AGIO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Agios Pharmaceuticals Inc (AGIO) Cash Flow - TradingKey
Agios Pharmaceuticals Inc (AGIO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Agios Pharmaceuticals Inc (AGIO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Agios Pharmaceuticals Inc (AGIO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
AGIO|Agios Pharmaceuticals Inc|Price:36.360|Chg%:+0.080 - TradingKey
Agios Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:AGIO - TradingView
Agios Pharmaceuticals Inc. (AGIO) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Agios Pharmaceuticals Inc (AGIO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Analysts Offer Insights on Healthcare Companies: Agios Pharma (AGIO) and Imunon (IMNN) - The Globe and Mail
Agios Pharmaceuticals (AGIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release - Yahoo Finance
Agios Reports Neutral Sickle Cell Data, Decides To Stop Development - Sahm
AGIO Shares Sink Nearly 7% After Scrapping the Tebapivat SCD Program - TradingView
H.C. Wainwright lowers Agios Pharma price target to $52 on trial data By Investing.com - Investing.com South Africa
H.C. Wainwright lowers Agios Pharma price target to $52 on trial data - Investing.com
Agios Pharmaceuticals (AGIO) Sees 13% Drop Following Trial Resul - GuruFocus
Agios Pharmaceuticals Reports Phase 2 Trial Results for Tebapiva - GuruFocus
Agios Pharmaceuticals (AGIO) Ends Development of Sickle Cell Dru - GuruFocus
AGIO Maintained by HC Wainwright & Co. -- Price Target Lowered t - GuruFocus
Agios scraps sickle cell treatment after trial shows limited benefit - Reuters
Agios Pharmaceuticals stock falls on trial update - Investing.com
Agios Pharma Drops Sickle Cell Disease Drug After Phase 2 Data Disappoint - MedCity News
Agios pares loss after abandoning sickle cell asset tebapivat (AGIO:NASDAQ) - Seeking Alpha
Agios scraps sickle cell drug - BioPharma Dive
Why Agios Pharma, A Novo Rival, Just Pulled A Bearish Move - Investor's Business Daily
Trial miss for Agios Pharma’s tebapivat in sickle cell disease - The Pharma Letter
Agios axes next-gen sickle cell candidate after it fails to best Novo’s asset - BioSpace
Agios Shelves Tebapivat In Sickle Cell, Weeks After MDS Exit - insights.citeline.com
Why Is AGIO Stock Falling Today? - TradingView
Agios shares tumble after discontinuing sickle cell disease programme following Phase 2 trial (AGIO) - Yahoo Finance
Agios halts tebapivat development in sickle cell disease - Investing.com
Agios halts tebapivat development in sickle cell disease By Investing.com - Investing.com Nigeria
Agios Pharmaceuticals stock falls on trial update By Investing.com - Investing.com Canada
Agios Pharmaceuticals Reports Phase 2 Tebapivat Sickle Cell Disease Results, Discontinues Development of the Candidate - Quiver Quantitative
Agios Pharmaceuticals Shares Down 12.6% Prema - Moomoo
Agios Provides Update on Phase 2 Trial of Tebapivat in Sickle Cell Disease - The Manila Times
Tebapivat 5 mg Arm: 47.1% Hemoglobin Response; Agios Won’t Advance - Stock Titan
Agios Pharmaceuticals (AGIO) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - MarketBeat
The Bull Case For Agios Pharmaceuticals (AGIO) Could Change Following FDA Priority Review For Mitapivat In Sickle Cell - simplywall.st
Agios gains FDA priority review for Pyrukynd label expansion - MSN
The Technical Signals Behind (AGIO) That Institutions Follow - Stock Traders Daily
Agios Pharmaceuticals (AGIO) Wins Priority Review, Is The Stock Now Fully Valued? - Sahm
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia - AOL.com
H.C. Wainwright Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating, Maintains Target Price $54 - Moomoo
AGIO 260717 45.00P (AGIO260717P45000) Latest Announcements - Moomoo
Agios Pharmaceuticals (NASDAQ: AGIO) director reports 1,447-share equity award and 2,894 RSUs - Stock Titan
Here's Why Shares in Novo Nordisk Rival, Agios Pharmaceutical, Soared This Week - AOL.com
Is Agios Pharmaceuticals (AGIO) A Bargain After FDA Priority Review For Mitapivat? - Yahoo Finance
Agios Pharmaceuticals (AGIO) Is Up 13.8% After FDA Grants Priority Review To Mitapivat In Sickle Cell Disease - Yahoo Finance
AGIO's Filing for Mitapivat in SCD Gets FDA's Priority Tag, Stock Up - The Globe and Mail
Strength Seen in Agios Pharmaceuticals (AGIO): Can Its 17.7% Jump Turn into More Strength? - Yahoo Finance
Agios Pharmaceuticals Inc (AGIO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.97%
0.83%
자본화:
|
볼륨(24시간):